AU2007242332B2 - Therapeutic agent for inflammatory bowel disease - Google Patents

Therapeutic agent for inflammatory bowel disease Download PDF

Info

Publication number
AU2007242332B2
AU2007242332B2 AU2007242332A AU2007242332A AU2007242332B2 AU 2007242332 B2 AU2007242332 B2 AU 2007242332B2 AU 2007242332 A AU2007242332 A AU 2007242332A AU 2007242332 A AU2007242332 A AU 2007242332A AU 2007242332 B2 AU2007242332 B2 AU 2007242332B2
Authority
AU
Australia
Prior art keywords
inflammatory bowel
bowel disease
compound
disease
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007242332A
Other languages
English (en)
Other versions
AU2007242332A1 (en
Inventor
Yuji Takebayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2007242332A1 publication Critical patent/AU2007242332A1/en
Application granted granted Critical
Publication of AU2007242332B2 publication Critical patent/AU2007242332B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007242332A 2006-04-13 2007-04-12 Therapeutic agent for inflammatory bowel disease Ceased AU2007242332B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-110869 2006-04-13
JP2006110869 2006-04-13
PCT/JP2007/000403 WO2007122812A1 (ja) 2006-04-13 2007-04-12 炎症性腸疾患治療薬

Publications (2)

Publication Number Publication Date
AU2007242332A1 AU2007242332A1 (en) 2007-11-01
AU2007242332B2 true AU2007242332B2 (en) 2012-02-02

Family

ID=38624731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007242332A Ceased AU2007242332B2 (en) 2006-04-13 2007-04-12 Therapeutic agent for inflammatory bowel disease

Country Status (12)

Country Link
US (1) US7820686B2 (ko)
EP (1) EP2005962B1 (ko)
JP (1) JP5058156B2 (ko)
KR (1) KR101390144B1 (ko)
CN (1) CN101420957B (ko)
AT (1) ATE554770T1 (ko)
AU (1) AU2007242332B2 (ko)
CA (1) CA2649256C (ko)
ES (1) ES2382673T3 (ko)
HK (1) HK1127964A1 (ko)
TW (1) TWI406858B (ko)
WO (1) WO2007122812A1 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI435725B (zh) * 2007-10-11 2014-05-01 Taiho Pharmaceutical Co Ltd The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis
TWI429439B (zh) * 2007-10-11 2014-03-11 Taiho Pharmaceutical Co Ltd And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
CN102920789A (zh) * 2012-11-29 2013-02-13 中央民族大学 治疗溃疡性结肠炎的药物制剂蒙药嘎日迪及其制备方法
CN104395307A (zh) 2013-06-17 2015-03-04 大鹏药品工业株式会社 地匹福林盐酸盐的稳定型晶体及其结晶化方法
WO2020035554A1 (en) * 2018-08-15 2020-02-20 Pharmacyl Ab A new medical treatment for pathologic inflammation
EP3860593A1 (en) * 2018-10-03 2021-08-11 Akebia Therapeutics Inc. Benzimidazole derivative for use in the treatment of inflammatory disorders
CN110638803A (zh) * 2019-10-24 2020-01-03 上海长海医院 Dencichine在制备治疗炎性肠病药物中的用途
CN114980898A (zh) * 2019-11-20 2022-08-30 安吉昂生物医药公司 用于治疗炎性肠病的方法
CN111686106B (zh) * 2020-04-05 2022-07-15 温州医科大学附属第一医院 提高Dicer表达的化合物在制备药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
US6479500B1 (en) * 1999-03-23 2002-11-12 Taiho Pharmaceutical Co., Ltd. Agents for alleviating side effects

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422360T1 (de) * 1996-04-05 2009-02-15 Kirin Brewery Verfahren zur herstellung einer substanz, die in keimenden saaten von gräsern vorkommt und proteine und unlösliche ballaststoffe enthält

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
US6479500B1 (en) * 1999-03-23 2002-11-12 Taiho Pharmaceutical Co., Ltd. Agents for alleviating side effects

Also Published As

Publication number Publication date
CA2649256A1 (en) 2007-11-01
KR20080108999A (ko) 2008-12-16
JP5058156B2 (ja) 2012-10-24
ES2382673T3 (es) 2012-06-12
EP2005962A9 (en) 2009-07-15
ATE554770T1 (de) 2012-05-15
JPWO2007122812A1 (ja) 2009-09-03
TWI406858B (zh) 2013-09-01
EP2005962A4 (en) 2009-09-23
EP2005962B1 (en) 2012-04-25
CN101420957B (zh) 2011-04-13
HK1127964A1 (en) 2009-10-09
CN101420957A (zh) 2009-04-29
CA2649256C (en) 2013-09-10
EP2005962A2 (en) 2008-12-24
AU2007242332A1 (en) 2007-11-01
TW200813025A (en) 2008-03-16
KR101390144B1 (ko) 2014-04-28
US20090209565A1 (en) 2009-08-20
WO2007122812A1 (ja) 2007-11-01
US7820686B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
AU2007242332B2 (en) Therapeutic agent for inflammatory bowel disease
ES2532210T3 (es) Métodos para el tratamiento concomitante de teofilina y febuxostat
US20170157131A1 (en) Antitumor effect potentiator and antitumor agent
WO2004082715A1 (ja) 炎症性腸疾患治療剤としての併用医薬
EP3458448A1 (en) Methods of using fasn inhibitors
WO2021047525A1 (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
CN105658645A (zh) 作为mpge-1抑制剂的哌啶基苯并咪唑衍生物
US8188105B2 (en) Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
SG186798A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
Pema Lesinurad sodium
CN112584836A (zh) 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途
JP4737686B2 (ja) 新しい医薬
US20100130475A1 (en) Preventive or therapeutic agent for inflammatory bowel diseases
JP5296699B2 (ja) チミジンホスホリラーゼ阻害剤を有効成分として含有する炎症性疾患の予防又は治療剤
TW200408386A (en) Medicine for renal failure containing oxaluric acid derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired